The Wall Street Journal
MARKETS & FINANCE
Economy & Business
Recap: European Central Bank Cuts Key Rate to 0.25%
How Much Would You Pay for Twitter Shares?
Select a Region: Global
Nov 7, 2013
Twitter Downgraded to Sell: ‘Simply Too Expensive’
One Wall Street analyst has already taken an ax to his Twitter Inc.'sTWTR +77.19% rating after shares popped on the first day of trading.
Pivotal Research Group senior analyst Brian Wieser cut Twitter to sell from buy and slapped a $30 price target on the social-messaging platform. The revised views came after Twitter shares opened at $45.10 on the New York Stock ExchangeNYX +0.46%, up 73% from the $26 initial public offering price.
black and white
Tesla Stock Options Trading Through the Roof Ahead of Earnings
24/7 Wall St.By Jon C. Ogg |
Market Currents |
Investing Ideas |
Dividends & Income |
Macro View |
Home » Become a Seeking Alpha Contributor
Become a Seeking Alpha Contributor
We're thrilled you're considering becoming a contributor! Here are some of the benefits of submitting articles to Seeking Alpha, the #1 website for sophisticated analysis of U.S. stock markets:
Contributors' article links are emailed to Seeking Alpha alert subscribers. More than 500,000 users receive alerts, which are sent every time a single-stock article is published.
Article links are also emailed to SA newsletter subscribers in digest format. We have 846,198 email subscribers.
Article links are syndicated all over the web. Your article headline will appear on Yahoo Finance, MSN Money, CNBC, MarketWatch, Bloomberg terminals, and many more places.
Average page-views per Premium article: 5,042
Cash & Benefits
Premium articles (articles that are exclusive to Seeking Alpha, more here) earn $10/thousand page-views (CPM).
Premium articles may also be selected by editors for SA Pro, our subscription-based research platform for professional investors. Pro articles receive a guaranteed minimum payment of $100-500. SA Pro contributors also receive free access to SA Pro for each article selected (see more details about SA Pro here).
There are two steps to becoming a contributor on Seeking Alpha:
Step 1: Register as a contributor
Once you're signed in on the website, click here to fill out your contributor details.
You will be prompted for your real name and contact details; this information will be kept private, and will not be shared on the Seeking Alpha website.
When you’ve finished filling out the requested information, click on "Register as a contributor." Congratulations, you're now registered as a Seeking Alpha contributor.
Step 2: Submit an article
Once you finish registering as a contributor, you will automatically be directed to the Submit an Article page where you can decide what kind of article you'd like to submit.
If you choose to write a Premium article, you will then be asked to submit your payment details so that Seeking Alpha can pay you for the Premium articles you have published
do the math.
you know I'm not long or short was thinking of buying and did research then shared.
just stating the facts.
I was checking to see if was released before put it in google and Nov 12, 2012 date came up and took me to ACAD website.
ACAD Website Under Press Release:
ACADIA Announces Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinson’s Disease Psychosis Trial
Pimavanserin Demonstrates Highly Significant Antipsychotic Efficacy and Maintenance of Motor Control in Parkinson’s Patients
Significant Improvements Also Observed in All Secondary and Exploratory Measures
Conference Call and Webcast to Be Held Today, November 27, 2012, at 8:00 am Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Nov. 27, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced successful top-line results from its pivotal Phase III trial evaluating the efficacy, tolerability and safety of pimavanserin in patients with Parkinson’s disease psychosis (PDP). Pimavanserin is ACADIA’s proprietary, non-dopaminergic product candidate that selectively blocks serotonin 5-HT2A receptors. Pimavanserin met the primary endpoint in the Phase III trial by demonstrating highly significant antipsychotic efficacy as measured using the 9-item SAPS-PD scale (p=0.001). Pimavanserin also met the key secondary endpoint for motoric tolerability as measured using Parts II and III of the Unified Parkinson’s Disease Rating Scale, or UPDRS. These results were further supported by a highly significant improvement in the secondary efficacy measure, the Clinical Global Impression Improvement, or CGI-I, scale (p=0.001). In addition, clinical benefits were observed in all exploratory efficacy measures with significant improvements in nighttime sleep, daytime wakefulness and caregiver burden. Consistent with previous studies, pimavanserin was safe and well tolerated in this Phase III trial.
“These data represent an unprecedented advance for Parkinson’s patients who suffer from the psychosis frequently associated with this disease,” said Jeffrey Cummings, M.D., Sc.D., Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. “Among Parkinson’s patients, psychosis is the leading cause of institutionalization a